Sec Form 4 Filing - Kummeth Charles R. @ BIO-TECHNE Corp - 2022-01-28

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Kummeth Charles R.
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (MM/DD/YY)
01/28/2022
(Street)
MINNEAPOLIS, MN55413
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 100 I By Step-Son
Common Stock 100 I By Step-Daughter
Common Stock 01/28/2022 M 938 A $ 106.59 197,539( 1 ) D
Common Stock 01/28/2022 M 799 A $ 125.05 198,338( 1 ) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $ 108.49 ( 2 ) 08/07/2022 Common Stock 100,450 100,450 D
Stock Options (Right to Buy) $ 106.59 01/28/2022 M 938 ( 2 ) 08/18/2023 Common Stock 938 $ 0 256,010 D
Stock Options (Right to Buy) $ 125.05 01/28/2022 M 799 ( 2 ) 08/09/2024 Common Stock 799 $ 0 194,771 D
Stock Options (Right to Buy) $ 177.32 ( 2 ) 08/08/2025 Common Stock 90,334 90,334 D
Stock Options (Right to Buy) $ 177.32 ( 3 ) 08/08/2025 Common Stock 60,222 60,222 D
Restricted Stock Units ( 4 ) ( 5 ) ( 5 ) Common Stock 16,937 16,937 D
Stock Options (Right to Buy) $ 190.41 ( 5 ) 08/07/2026 Common Stock 85,725 85,725 D
Stock Options (Right to Buy) $ 190.41 ( 6 ) 08/07/2026 Common Stock 57,150 57,150 D
Restricted Stock Units ( 4 ) ( 7 ) ( 7 ) Common Stock 12,879 12,879 D
Stock Options (Right to Buy) $ 267.87 ( 7 ) 08/05/2027 Common Stock 57,442 57,442 D
Stock Options (Right to Buy) $ 267.87 ( 8 ) 08/05/2027 Common Stock 38,295 38,295 D
Stock Options (Right to Buy) $ 267.87 ( 9 ) 08/05/2027 Common Stock 16,650 16,650 D
Stock Options (Right to Buy) $ 267.87 ( 10 ) 08/05/2027 Common Stock 16,650 16,650 D
Restricted Stock Units ( 4 ) ( 11 ) ( 11 ) Common Stock 8,016 8,016 D
Stock Options (Right to Buy) $ 481.82 ( 11 ) 08/06/2028 Common Stock 31,315 31,315 D
Stock Options (Right to Buy) $ 481.82 ( 12 ) 08/06/2028 Common Stock 20,876 20,876 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kummeth Charles R.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN55413
X Chief Executive Officer
Signatures
/s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed. 02/01/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024.
( 2 )Fully exercisable.
( 3 )Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.
( 4 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
( 5 )Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
( 6 )Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.
( 7 )Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
( 8 )Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
( 9 )Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
( 10 )Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.
( 11 )Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
( 12 )Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.